静脉铁剂改善慢性心衰合并铁缺乏患者骨骼肌能量代谢
本研究纳入40例慢性心衰合并铁缺乏患者,按贫血状态分层随机接受单次总剂量异麦芽糖铁或安慰剂输注。2周后铁剂组骨骼肌磷酸肌酸恢复半时间(PCr t1/2)较安慰剂组缩短6.8秒,ADP恢复半时间缩短5.3秒,且铁蛋白、转铁蛋白饱和度及心衰症状改善,而血红蛋白无显著变化。提示静脉补铁可能通过改善线粒体功能增强骨骼肌能量代谢。
要点
- 慢性心衰合并铁缺乏患者单次总剂量静脉铁剂可改善骨骼肌能量代谢。
- PCr t1/2缩短独立于血红蛋白变化,提示线粒体功能改善机制。
- 贫血与非贫血亚组PCr t1/2均有改善趋势,不良反应与安慰剂相似。
核心结论
- 慢性心衰合并铁缺乏患者单次总剂量异麦芽糖铁输注耐受良好,2周时骨骼肌PCr t1/2加快,提示线粒体功能改善。
- 骨骼肌能量代谢改善可能是静脉补铁在血红蛋白变化轻微时仍带来临床获益的重要机制。
研究设计与样本
- 随机、双盲、安慰剂对照研究,纳入40例慢性心衰(NYHA≥II级,LVEF≤45%)合并铁缺乏患者。
- 按贫血状态分层(贫血与非贫血各50%)1:1随机接受单次总剂量异麦芽糖铁或生理盐水安慰剂输注。
- 主要终点为2周时磷磁共振波谱测定的PCr恢复半时间(PCr t1/2)。
主要发现
- 2周时铁剂组PCr t1/2较安慰剂组校正后差异为-6.8秒(95%CI 11.5至-2.1,P=0.006)。
- ADP恢复半时间差异为-5.3秒(95%CI -9.7至-0.9,P=0.02)。
- 铁蛋白升高304 ng/mL(95%CI 217-391,P<0.0001),转铁蛋白饱和度升高6.8%(95%CI 2.7-10.8,P=0.002)。
- NYHA分级改善-0.23(95%CI -0.46至-0.01,P=0.04),静息呼吸频率降低0.7次/分(95%CI -1.2至-0.2,P=0.009),运动后Borg呼吸困难评分降低2.0(95%CI -3.7至-0.3,P=0.04)。
- 血红蛋白变化2.4 g/L(95%CI -3.5至8.4,P=0.41),两组不良事件相似。
关键数值与推荐
- 铁缺乏定义:铁蛋白<100 μg/L,或铁蛋白100-300 μg/L且转铁蛋白饱和度<20%。
- 入组标准:慢性心衰、NYHA≥II级、LVEF≤45%。
- 主要终点PCr t1/2的组间校正差异为-6.8秒(95%CI 11.5至-2.1,P=0.006)。
临床怎么用
- 对慢性心衰合并铁缺乏患者,可考虑单次总剂量静脉异麦芽糖铁输注以改善骨骼肌能量代谢和症状。
- 补铁获益可能不依赖血红蛋白升高,评估铁缺乏并纠正铁储备具有临床意义。
局限性
- 样本量较小(40例),研究结论需更大规模试验验证。
- 随访仅2周,长期骨骼肌能量代谢及临床硬终点获益未评估。
- 单次总剂量输注方案与其他补铁方案的比较未涉及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Iron repletion augments exercise capacity in chronic heart failure (HF), but there is a lack of mechanistic data explaining how iron could augment exercise performance despite minimal changes in hemoglobin (Hb). Besides Hb, iron is an obligate component of mitochondrial enzymes that generate cellular energy in the form of adenosine triphosphate and phosphocreatine (PCr). Dynamic phosphorus magnetic resonance spectroscopy is a noninvasive tool that quantifies in vivo muscle energetics by measuring the kinetics of PCr recovery after exertion. We tested the hypothesis that intravenous iron repletion in chronic HF enhances skeletal muscle energetics as reflected by shorter PCr recovery half-times (PCr t1/2) on phosphorus magnetic resonance spectroscopy. METHODS: We enrolled 40 patients (50% anemic) with chronic HF, New York Heart Association class ≥II, left ventricular ejection fraction ≤45%, and iron deficiency (ferritin<100 μg/L or 100-300 μg/L with transferrin saturation <20%). Subjects underwent stratified (anemic versus nonanemic) randomization (1:1) to a single, double-blinded, total dose infusion of iron isomaltoside or saline placebo with end points reassessed early at 2 weeks posttreatment to minimize confounding from exercise adaptation. The primary end point was PCr t1/2 at 2 weeks. Secondary end points included ADP recovery half-time (ADP t1/2; energetic marker), iron status, symptoms, Hb, exercise capacity, and safety. RESULTS: In the total population, treatment groups were similar at baseline. At 2 weeks, iron isomaltoside improved PCr t1/2 (adjusted difference, -6.8 s; 95% CI, 11.5 to -2.1; P=0.006), ADP t1/2 (-5.3 s; 95% CI, -9.7 to -0.9; P=0.02), ferritin (304 ng/mL; 95% CI, 217-391; P<0.0001), transferrin saturation (6.8%; 95% CI, 2.7-10.8; P=0.002), New York Heart Association class (-0.23; 95% CI, -0.46 to -0.01; P=0.04), resting respiratory rate (-0.7 breaths/min; 95% CI, -1.2 to -0.2; P=0.009), and postexercise Borg dyspnea score (-2.0; 95% CI, -3.7 to -0.3; P=0.04), but not Hb (2.4 g/L; 95% CI, -3.5 to 8.4; P=0.41). Adverse events were similar between groups. In subgroup analyses, iron isomaltoside improved PCr t1/2 in anemic (-8.4 s; 95% CI, -16.7 to -0.2; P=0.04) and nonanemic (-5.2 s; 95% CI, -10.6 to 0.2; P=0.06) cohorts. CONCLUSIONS: In patients with chronic HF and iron deficiency, a total repletion dose of iron isomaltoside given at a single sitting is well tolerated and associated with faster skeletal muscle PCr t1/2 at 2 weeks, implying better mitochondrial function. Augmented skeletal muscle energetics might therefore be an important mechanism via which iron repletion confers benefits in chronic HF despite minimal Hb changes. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005592-13/GB . Unique identifier: EudraCT 2012-005592-13.
引用
- Charles-Edwards G, Amaral N, Sleigh A, et al. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency. Circulation. 2019. PMID: 30776909. doi:10.1161/CIRCULATIONAHA.118.038516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。